On Tuesday, Zenas Biopharma Inc (NASDAQ: ZBIO) was -12.65% drop from the session before settling in for the closing price of $7.75. A 52-week range for ZBIO has been $5.83 – $26.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -45.00% over the last five years. When this article was written, the company’s average yearly earnings per share was at 62.98%. With a float of $10.15 million, this company’s outstanding shares have now reached $41.79 million.
The firm has a total of 130 workers. Let’s measure their productivity. In terms of profitability, gross margin is 100.0%, operating margin of -3277.74%, and the pretax margin is -3131.16%.
Zenas Biopharma Inc (ZBIO) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Zenas Biopharma Inc stocks. The insider ownership of Zenas Biopharma Inc is 75.71%, while institutional ownership is 32.41%. The most recent insider transaction that took place on Feb 18 ’25, was worth 166,750. In this transaction Chief Executive Officer of this company bought 25,000 shares at a rate of $6.67, taking the stock ownership to the 266,155 shares. Before that another transaction happened on Feb 07 ’25, when Company’s Director bought 10,000 for $7.76, making the entire transaction worth $77,600. This insider now owns 47,000 shares in total.
Zenas Biopharma Inc (ZBIO) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 62.98% per share during the next fiscal year.
Zenas Biopharma Inc (NASDAQ: ZBIO) Trading Performance Indicators
You can see what Zenas Biopharma Inc (ZBIO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 56.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.90, a number that is poised to hit -1.11 in the next quarter and is forecasted to reach -4.04 in one year’s time.
Technical Analysis of Zenas Biopharma Inc (ZBIO)
Analysing the last 5-days average volume posted by the [Zenas Biopharma Inc, ZBIO], we can find that recorded value of 0.36 million was better than the volume posted last year of 0.2 million. As of the previous 9 days, the stock’s Stochastic %D was 23.03%. Additionally, its Average True Range was 0.88.
During the past 100 days, Zenas Biopharma Inc’s (ZBIO) raw stochastic average was set at 5.65%, which indicates a significant increase from 2.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 107.58% in the past 14 days, which was higher than the 104.10% volatility it showed in the past 100 days.
Now, the first resistance to watch is $7.60. This is followed by the second major resistance level at $8.42. The third major resistance level sits at $8.88. If the price goes on to break the first support level at $6.32, it is likely to go to the next support level at $5.86. Now, if the price goes above the second support level, the third support stands at $5.04.
Zenas Biopharma Inc (NASDAQ: ZBIO) Key Stats
There are 41,799K outstanding shares of the company, which has a market capitalization of 282.93 million. As of now, sales total 5,000 K while income totals -156,988 K. Its latest quarter income was 5,000 K while its last quarter net income were -52,604 K.
